Hydrocortisone Sodium Succinate for Injection
Indicatios:
Hydrocortisone Sodium Succinate for Injection is indicated for any condition in which rapid and intense corticosteroid effect is required such as:
1. Endocrine disorders
Primary or secondary adrenocortical insufficiency
2. Collagen diseases
Systemic lupus erythematosus
3. Dermatological diseases
Severe erythema multiforme (Stevens-Johnson syndrome)
4. Allergic states
Bronchial asthma, anaphylactic reactions
5. Gastro-intestinal diseases
Ulcerative colitis, Crohn's disease
6. Respiratory diseases
Aspiration of gastric contents
7. Medical emergencies
Hydrocortisone Sodium Succinate for Injection is indicated in the treatment of shock secondary to adrenocortical insufficiency or shock unresponsive to conventional therapy when adrenocortical insufficiency may be present.
Dosage and administration：
This medicine may be administered by intravenous injection, by intravenous infusion, or by intramuscular injection, the preferred method for initial emergency use being intravenous injection. Following the initial emergency period, consideration should be given to employing a longer-acting injectable preparation or an oral preparation.
Dosage usually ranges from 100 mg to 500 mg depending on the severity of the condition, administered by intravenous injection over a period of one to ten minutes. This dose may be repeated at intervals of 2, 4 or 6 hours as indicated by the patient's response and clinical condition.
This medicine is not recommended for intrathecal or epidural use.
Contraindications:
Hydrocortisone is contraindicated:
• in patients where there is known hypersensitivity to the active substance or any of the excipients.
• in patients who have systemic fungal infection unless specific anti-infective therapy is employed.
Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids.
Precautions:
1.Undesirable effects may be minimised by using the lowest effective dose for the minimum period. Frequent patient review is required to appropriately titrate the dose against disease activity .
2.Adrenal cortical atrophy develops during prolonged therapy and may persist for months after stopping treatment. In patients who have received more than physiological doses of systemic corticosteroids (approximately 30 mg hydrocortisone) for greater than 3 weeks, withdrawal should not be abrupt.
3. Immunosuppressant Effects/Increased Susceptibility to Infections.
For other precautions, please consult your doctor.
Drug interactions:
1.CYP3A4 INHIBITORS - May decrease hepatic clearance and increase the plasma concentrations of hydrocortisone.
2.CYP3A4 INDUCERS - May increase hepatic clearance and decrease the plasma concentrations of hydrocortisone.
3.CYP3A4 SUBSTRATES - In the presence of another CYP3A4 substrate, the hepatic clearance of hydrocortisone may be affected, with corresponding dosage adjustments required.
For other medications that may interact with hydrocortisone, you should consult your doctor before using them.
Storage:
Store below 25°C.